Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Related to this article
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.
In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.
Advertisement
Advertisement
Trending on OncLive
1
Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC
2
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
3
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
4
EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer
5